dr. nielsen on the clinical utility of ki67 in breast cancer
Published 11 years ago • 564 plays • Length 0:49Download video MP4
Download video MP3
Similar videos
-
1:01
dr. nielsen on the challenges of using ki67 as a tool in breast cancer
-
1:19
dr. nielsen on the pros and cons of the ki67 assay in breast cancer
-
1:29
dr. nielsen discusses using a ki67 assay in breast cancer
-
10:05
ki-67 shows proven clinical utility as a predictive clincal biomarkers for breast cancer
-
1:36
dr. verma on her2 testing and the utility of ki67
-
6:09
ki-67 index after neoadjuvant et as a prognostic biomarker for hr /her2- early breast cancer
-
1:52
dr. ellis discusses ki67 as a treatment monitoring biomarker
-
2:07
dr. nielsen discusses the pam50 assay
-
3:17
dr. goncalves discusses the development of a standardized ki-67 assay
-
2:25
comment: lumina results show that women with low levels of the ki67 biomarker can avoid outcomes...
-
1:23
brock schroeder discusses bci findings in er breast cancer
-
2:07
lumina results: women with low levels of the ki67 biomarker can avoid outcomes related to rt
-
0:50
dr. ellis discusses the cell-proliferation marker ki67
-
1:12
the use of ki-67, a proliferation marker, for guiding treatment decisions in breast cancer patients
-
1:30
utilizing genomic assays for decision making in early stage breast cancer
-
1:21
the use of the ki-67 in deciding which patients with hr breast cancer can safely avoid chemotherapy
-
1:17
perelisa: de-escalated therapy for hr /her2 bc with ki67 response following 2-week letrozole
-
4:04
stanford oncologist, douglas blayney, md, discusses breast cancer
-
1:40
dr. o'shaughnessy on the future of breast cancer biomarkers